78 related articles for article (PubMed ID: 22740352)
1. Attenuation of treatment effect due to measurement variability in assessment of progression-free survival.
Hong S; Schmitt N; Stone A; Denne J
Pharm Stat; 2012; 11(5):394-402. PubMed ID: 22740352
[TBL] [Abstract][Full Text] [Related]
2. Measurement error in the timing of events: effect on survival analyses in randomized clinical trials.
Korn EL; Dodd LE; Freidlin B
Clin Trials; 2010 Dec; 7(6):626-33. PubMed ID: 20819840
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
Wilkerson J; Fojo T
Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power?
Hernández AV; Eijkemans MJ; Steyerberg EW
Ann Epidemiol; 2006 Jan; 16(1):41-8. PubMed ID: 16275011
[TBL] [Abstract][Full Text] [Related]
5. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
[TBL] [Abstract][Full Text] [Related]
7. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
Pond GR; Abbasi S
Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
[TBL] [Abstract][Full Text] [Related]
8. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials.
Sridhara R; Mandrekar SJ; Dodd LE
Clin Cancer Res; 2013 May; 19(10):2613-20. PubMed ID: 23669421
[TBL] [Abstract][Full Text] [Related]
9. Effects of sources of variability on sample sizes required for RCTs, applied to trials of lipid-altering therapies on carotid artery intima-media thickness.
Gould AL; Koglin J; Bain RP; Pinto CA; Mitchel YB; Pasternak RC; Sapre A
Clin Trials; 2009 Aug; 6(4):305-19. PubMed ID: 19667027
[TBL] [Abstract][Full Text] [Related]
10. A Proposal for Progression-Free Survival Assessment in Patients with Early Progressive Cancer.
Tanase T; Hamada C; Yoshino T; Ohtsu A
Anticancer Res; 2017 Oct; 37(10):5851-5855. PubMed ID: 28982911
[TBL] [Abstract][Full Text] [Related]
11. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings.
Bedard PL; Krzyzanowska MK; Pintilie M; Tannock IF
J Clin Oncol; 2007 Aug; 25(23):3482-7. PubMed ID: 17687153
[TBL] [Abstract][Full Text] [Related]
12. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
13. Adjustment for baseline measurement error in randomized controlled trials induces bias.
Chan SF; Macaskill P; Irwig L; Walter SD
Control Clin Trials; 2004 Aug; 25(4):408-16. PubMed ID: 15296815
[TBL] [Abstract][Full Text] [Related]
14. Challenges of subgroup analyses in multinational clinical trials: experiences from the MERIT-HF trial.
Wedel H; Demets D; Deedwania P; Fagerberg B; Goldstein S; Gottlieb S; Hjalmarson A; Kjekshus J; Waagstein F; Wikstrand J;
Am Heart J; 2001 Sep; 142(3):502-11. PubMed ID: 11526365
[TBL] [Abstract][Full Text] [Related]
15. Sample size determination for comparing several survival curves with unequal allocations.
Halabi S; Singh B
Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
[TBL] [Abstract][Full Text] [Related]
16. Blinded sample size reassessment in non-inferiority and equivalence trials.
Friede T; Kieser M
Stat Med; 2003 Mar; 22(6):995-1007. PubMed ID: 12627414
[TBL] [Abstract][Full Text] [Related]
17. Analysis of survival data with missing measurements of a time-dependent binary covariate.
Halabi S; Wun CC; Davis BR
J Biopharm Stat; 2003 May; 13(2):253-70. PubMed ID: 12729393
[TBL] [Abstract][Full Text] [Related]
18. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas.
McGirt MJ; Chaichana KL; Attenello FJ; Weingart JD; Than K; Burger PC; Olivi A; Brem H; Quinoñes-Hinojosa A
Neurosurgery; 2008 Oct; 63(4):700-7; author reply 707-8. PubMed ID: 18981880
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of three definitions of progression-free survival in preoperative cancer therapy (JCOG0801-A).
Nakamura K; Shibata T; Takashima A; Yamamoto S; Fukuda H
Jpn J Clin Oncol; 2012 Oct; 42(10):896-902. PubMed ID: 22844128
[TBL] [Abstract][Full Text] [Related]
20. Sample size calculation for the weighted rank statistics with paired survival data.
Jung SH
Stat Med; 2008 Jul; 27(17):3350-65. PubMed ID: 18205148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
